HU-345
 | |
| Identifiers | |
|---|---|
IUPAC name
| |
| PubChem CID | |
| ChemSpider |
|
| ChEMBL | |
| Chemical and physical data | |
| Formula | C21H24O3 |
| Molar mass | 324.420 g·mol−1 |
| 3D model (JSmol) | |
SMILES
| |
InChI
| |
| (verify) | |
HU-345 (cannabinol quinone) is a drug that is able to inhibit aortic ring angiogenesis more potently than its parent compound cannabinol.[1][2]
See also
References
- ↑ Kogan NM, Blázquez C, Alvarez L, Gallily R, Schlesinger M, Guzmán M, Mechoulam R (July 2006). "A cannabinoid quinone inhibits angiogenesis by targeting vascular endothelial cells". Molecular Pharmacology. 70 (1): 51–9. doi:10.1124/mol.105.021089. PMID 16571653. S2CID 4830577.
- ↑ US patent 0092584, Mechoulam R, Kogan NM, Rabinowitz R, Schlesinger M, "Therapeutic Use of Quinonoid Derivatives of Cannabinoids", granted 2011-04-21
| Phytocannabinoids |
| ||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Endocannabinoids |
| ||||||||||||||||||||||||||||||||||||||||||||||||||
| Synthetic cannabinoid receptor agonists / neocannabinoids |
| ||||||||||||||||||||||||||||||||||||||||||||||||||
| Allosteric CBR ligands |
| ||||||||||||||||||||||||||||||||||||||||||||||||||
| Endocannabinoid enhancers (inactivation inhibitors) |
| ||||||||||||||||||||||||||||||||||||||||||||||||||
| Anticannabinoids (antagonists/inverse agonists/antibodies) |
| ||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.